Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Small Untranslated | 2 | 2020 | 19 | 1.200 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 114 | 1.080 |
Why?
|
| RNA, Long Noncoding | 2 | 2025 | 170 | 0.980 |
Why?
|
| Software | 3 | 2025 | 389 | 0.950 |
Why?
|
| Transcriptome | 3 | 2025 | 387 | 0.940 |
Why?
|
| Sequence Analysis, RNA | 4 | 2025 | 174 | 0.880 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 8 | 0.650 |
Why?
|
| Liver Cirrhosis | 4 | 2025 | 173 | 0.620 |
Why?
|
| Gene Expression Profiling | 6 | 2025 | 770 | 0.600 |
Why?
|
| Statistics as Topic | 1 | 2018 | 145 | 0.540 |
Why?
|
| Hepatic Stellate Cells | 2 | 2024 | 24 | 0.400 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 102 | 0.340 |
Why?
|
| Ondansetron | 2 | 2024 | 33 | 0.320 |
Why?
|
| Simvastatin | 2 | 2024 | 26 | 0.320 |
Why?
|
| Federal Government | 1 | 2009 | 19 | 0.320 |
Why?
|
| Education | 1 | 2009 | 68 | 0.310 |
Why?
|
| Schizophrenia | 2 | 2024 | 263 | 0.270 |
Why?
|
| Antipsychotic Agents | 2 | 2024 | 301 | 0.260 |
Why?
|
| Molecular Sequence Annotation | 2 | 2025 | 65 | 0.260 |
Why?
|
| Memory, Long-Term | 2 | 2016 | 7 | 0.250 |
Why?
|
| Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 7 | 0.230 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 465 | 0.220 |
Why?
|
| Pakistan | 5 | 2024 | 17 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 313 | 0.220 |
Why?
|
| Gene Expression | 3 | 2019 | 840 | 0.220 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2025 | 168 | 0.220 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2024 | 15 | 0.220 |
Why?
|
| Chromatin | 3 | 2022 | 608 | 0.210 |
Why?
|
| Machine Learning | 1 | 2025 | 177 | 0.210 |
Why?
|
| Hepatocytes | 1 | 2025 | 218 | 0.200 |
Why?
|
| Mice | 10 | 2024 | 10844 | 0.200 |
Why?
|
| Fatty Liver | 1 | 2023 | 108 | 0.190 |
Why?
|
| Enterovirus | 1 | 2022 | 1 | 0.190 |
Why?
|
| Abortion, Veterinary | 1 | 2022 | 1 | 0.190 |
Why?
|
| Camelus | 1 | 2022 | 1 | 0.190 |
Why?
|
| Cognition | 2 | 2024 | 484 | 0.190 |
Why?
|
| MicroRNAs | 3 | 2019 | 687 | 0.180 |
Why?
|
| Cicatrix | 1 | 2022 | 61 | 0.180 |
Why?
|
| Animals | 13 | 2024 | 20663 | 0.180 |
Why?
|
| Viruses | 1 | 2022 | 81 | 0.180 |
Why?
|
| Crohn Disease | 1 | 2022 | 110 | 0.170 |
Why?
|
| Microbiota | 1 | 2022 | 129 | 0.170 |
Why?
|
| DNA Methylation | 3 | 2018 | 292 | 0.160 |
Why?
|
| Liver | 1 | 2025 | 855 | 0.160 |
Why?
|
| Brain | 2 | 2018 | 1552 | 0.160 |
Why?
|
| RNA, Bacterial | 1 | 2020 | 74 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2020 | 195 | 0.150 |
Why?
|
| Cattle | 1 | 2020 | 310 | 0.150 |
Why?
|
| Rats | 2 | 2020 | 1980 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 81 | 0.150 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 15 | 0.150 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 28 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2020 | 120 | 0.150 |
Why?
|
| Base Sequence | 2 | 2018 | 1331 | 0.150 |
Why?
|
| Organogenesis | 1 | 2018 | 39 | 0.150 |
Why?
|
| Internet | 2 | 2020 | 469 | 0.150 |
Why?
|
| beta-Galactosidase | 1 | 2018 | 77 | 0.150 |
Why?
|
| Codon | 1 | 2018 | 56 | 0.140 |
Why?
|
| Nucleic Acids | 1 | 2019 | 60 | 0.140 |
Why?
|
| RNA, Viral | 1 | 2020 | 276 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2020 | 149 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2020 | 131 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 236 | 0.140 |
Why?
|
| Humans | 14 | 2025 | 63445 | 0.140 |
Why?
|
| Homovanillic Acid | 1 | 2017 | 6 | 0.140 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 11 | 0.140 |
Why?
|
| Monoamine Oxidase | 1 | 2017 | 8 | 0.140 |
Why?
|
| Paroxetine | 1 | 2017 | 16 | 0.140 |
Why?
|
| Fluoxetine | 1 | 2017 | 44 | 0.130 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2017 | 30 | 0.130 |
Why?
|
| Computational Biology | 2 | 2018 | 356 | 0.130 |
Why?
|
| Stem Cells | 1 | 2018 | 259 | 0.130 |
Why?
|
| Hippocampus | 1 | 2018 | 270 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2017 | 162 | 0.130 |
Why?
|
| Affect | 1 | 2017 | 125 | 0.130 |
Why?
|
| Kidney | 1 | 2018 | 446 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 424 | 0.120 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2015 | 10 | 0.120 |
Why?
|
| Oryzias | 1 | 2015 | 5 | 0.120 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 385 | 0.120 |
Why?
|
| Histones | 2 | 2016 | 481 | 0.120 |
Why?
|
| Gyrus Cinguli | 1 | 2015 | 57 | 0.120 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 60 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2015 | 89 | 0.120 |
Why?
|
| Online Systems | 1 | 2015 | 20 | 0.120 |
Why?
|
| Neuronal Plasticity | 1 | 2015 | 150 | 0.110 |
Why?
|
| Behavior, Animal | 1 | 2015 | 230 | 0.110 |
Why?
|
| Self-Injurious Behavior | 1 | 2014 | 47 | 0.100 |
Why?
|
| Serotonin Antagonists | 1 | 2013 | 32 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 172 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 216 | 0.090 |
Why?
|
| Depression | 1 | 2017 | 894 | 0.080 |
Why?
|
| Schizophrenic Psychology | 2 | 2024 | 66 | 0.080 |
Why?
|
| Male | 8 | 2025 | 29891 | 0.080 |
Why?
|
| Education, Graduate | 1 | 2009 | 16 | 0.080 |
Why?
|
| Emigration and Immigration | 1 | 2009 | 26 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2019 | 1537 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2024 | 739 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2024 | 5680 | 0.070 |
Why?
|
| Young Adult | 3 | 2024 | 4694 | 0.060 |
Why?
|
| Adolescent | 3 | 2024 | 6245 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2024 | 41 | 0.050 |
Why?
|
| Adult | 4 | 2025 | 16824 | 0.050 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 60 | 0.050 |
Why?
|
| Antigens, Nuclear | 1 | 2022 | 20 | 0.050 |
Why?
|
| Female | 5 | 2025 | 32880 | 0.050 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Ethers | 1 | 2022 | 17 | 0.050 |
Why?
|
| Spiro Compounds | 1 | 2022 | 11 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2022 | 45 | 0.050 |
Why?
|
| Superovulation | 1 | 2022 | 3 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 35 | 0.050 |
Why?
|
| Immunomodulation | 1 | 2022 | 30 | 0.050 |
Why?
|
| Embryo Transfer | 1 | 2022 | 25 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 160 | 0.050 |
Why?
|
| Collagen | 1 | 2022 | 123 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3396 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2019 | 43 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1172 | 0.040 |
Why?
|
| Nephrons | 1 | 2018 | 7 | 0.040 |
Why?
|
| Macrophages | 1 | 2025 | 1039 | 0.040 |
Why?
|
| Base Composition | 1 | 2018 | 30 | 0.040 |
Why?
|
| Proteostasis | 1 | 2018 | 11 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2019 | 383 | 0.040 |
Why?
|
| Nucleotides | 1 | 2018 | 49 | 0.040 |
Why?
|
| Transgenes | 1 | 2019 | 187 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2018 | 185 | 0.040 |
Why?
|
| Phenotype | 1 | 2022 | 1207 | 0.040 |
Why?
|
| Middle Aged | 3 | 2024 | 17613 | 0.030 |
Why?
|
| Disease | 1 | 2017 | 27 | 0.030 |
Why?
|
| Amino Acids | 1 | 2018 | 147 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2017 | 7 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 283 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 116 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 301 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 265 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 199 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 268 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 2187 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 896 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 790 | 0.030 |
Why?
|
| Mammals | 1 | 2017 | 218 | 0.030 |
Why?
|
| Genomics | 1 | 2019 | 370 | 0.030 |
Why?
|
| Suicidal Ideation | 1 | 2017 | 117 | 0.030 |
Why?
|
| Protein Folding | 1 | 2017 | 267 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 1277 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1147 | 0.030 |
Why?
|
| Genome, Human | 1 | 2017 | 237 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2017 | 322 | 0.030 |
Why?
|
| Fear | 1 | 2015 | 70 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 1592 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1147 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 14447 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 642 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2334 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 359 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 1513 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2157 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1119 | 0.030 |
Why?
|
| Problem Solving | 1 | 2014 | 32 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2018 | 2109 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1353 | 0.030 |
Why?
|
| Brazil | 1 | 2013 | 100 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 298 | 0.020 |
Why?
|
| Checklist | 1 | 2013 | 73 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1617 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 134 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1553 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 266 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 390 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1408 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 392 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 574 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 6658 | 0.020 |
Why?
|
| Mutation | 1 | 2017 | 2612 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2458 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 3768 | 0.010 |
Why?
|